Inherited thrombophilias and anticoagulation in pregnancy

Best Practice and Research: Clinical Obstetrics and Gynaecology

Volumn 17, Issue 3, 2003, Pages 471-489

  Bowles, Louise ^a   Cohen, Hannah ^a  

^a UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

Author keywords

Anticoagulation; Inherited thrombophilia; Low molecular weight heparin; Pregnancy

Indexed keywords

ACETYLSALICYLIC ACID; ANALGESIC AGENT; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BLOOD CLOTTING FACTOR 10A; CALCIUM; DALTEPARIN; DANAPAROID; DEXTRAN; ENOXAPANN; ENOXAPARIN; FONDAPARINUX; HEPARIN; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; NONSTEROID ANTIINFLAMMATORY AGENT; PHYTOMENADIONE; PROGESTERONE DERIVATIVE; PROTAMINE SULFATE; PROTHROMBIN COMPLEX; RECOMBINANT HIRUDIN; TINZAPARIN; UNCLASSIFIED DRUG; VITAMIN K GROUP; WARFARIN; XIMELAGATRAN;

ANTICOAGULATION; BLEEDING; BRAIN HEMORRHAGE; BREAST FEEDING; CENTRAL NERVOUS SYSTEM MALFORMATION; CLINICAL TRIAL; CONGENITAL HEART DISEASE; CONGENITAL HYDROCEPHALUS; DELIVERY; DOSE CALCULATION; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG MONITORING; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SAFETY; EMBRYOPATHY; FAMILY HISTORY; FEMALE; FETAL HEMORRHAGE; FETOMATERNAL TRANSFUSION; FETUS MALFORMATION; HIGH RISK PREGNANCY; HUMAN; LONG TERM CARE; LOW DRUG DOSE; LUNG EMBOLISM; MATERNAL DISEASE; OSTEOPENIA; PARTIAL THROMBOPLASTIN TIME; PREGNANCY; PRENATAL DIAGNOSIS; PRIORITY JOURNAL; PUERPERIUM; REVIEW; RISK ASSESSMENT; SKIN NECROSIS; SPONTANEOUS ABORTION; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOPHILIA; THROMBOSIS PREVENTION; VEIN THROMBOSIS;

EID: 0037704395     PISSN: 15216934     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1521-6934(03)00012-9     Document Type: Review

References (80)

1. Stirling Y, Woolf L, North WR et al. Haemostasis in normal pregnancy. Thrombosis and Haemostasis 1984; 52: 176-182.
2. Ramsay JE, McColl MD, Clark P et al. Activated protein C resistance in normal pregnancy. British Journal of Obstetrics and Gynaecology 1998; 105: 473-474.
3. Cumming AM, Tait RC, Fildes S et al. Development of resistance to activated protein C during pregnancy. British Journal of Haematology 1995; 90: 725-727.
4. Lewis G. Why mothers die 1997-1999. The Fifth Report of the Confidential Enquires into Maternal Deaths in the United Kingdom. 2001. pp. 22-75, ISBN 011322253X.
5. McColl MD, Ramsay JE, Tait RC et al. Risk factors for pregnancy associated venous thromboembolism. Thrombosis and Haemostasis 1997; 78: 1183-1188.
6. Gerhardt A, Scharf RE, Beckmann MW et al. Prothrombin and factor V mutations in women with a history of thrombosis during pregnancy and the puerperium. New England Journal of Medicine 2000; 342: 374-380.
7. Conard J, Horellou MH, Van Dreden P et al. Thrombosis and pregnancy in congenital deficiencies in AT III, protein C or protein S: Study of 78 women. Thrombosis and Haemostasis 1990; 63: 319-320.
8. Friederich PW, Sanson BJ, Simioni P et al. Frequency of pregnancy-related venous thromboembolism in anticoagulant factor-deficient women: Implications for prophylaxis. Annals of Internal Medicine 1996; 125: 955-960.
9. Brill-Edwards P, Ginsberg JS, Gent M et al. Safety of withholding heparin in pregnant women with a history of venous thromboembolism. New England Journal of Medicine 2000; 343: 1439-1444.
10. Rees DC, Cox M & Clegg JB. World distribution of factor V Leiden. Lancet 1995; 346: 1133-1134.
11. Poort SR, Rosendaal FR, Reitsma PH & Bertina RM. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88: 3698-3703.
12. Finazzi G, Caccia R & Barbui T. Different prevalence of thromboembolism in the subtypes of congenital antithrombin III deficiency: Review of 404 cases. Thrombosis and Haemostasis 1987; 58: 1094.
13. Thrombosis and Haemostasis Task Force, Investigation and management of heritable thrombophilia. British Journal of Haematology 2001; 114: 512-528.
14. Franco RF, Trip MD, Ten Cate H et al. The 20210 G-A mutation in the 3′-untranslated region of the prothrombin gene and the risk for arterial thrombotic disease. British Journal of Haematology 1999; 104: 50-54.
15. Rosendaal FR, Siscovick DS, Schwartz SM et al. A common prothrombin variant (20210 G to A) increases the risk of myocardial infarction in young women. Blood 1997; 90: 1747-1750.
16. De Stefano V, Chiusolo P, Paciaroni K et al. Prothrombin G20210A mutant genotype is a risk factor for cerebrovascular ischaemic disease in young patients. Blood 1998; 91: 3562-3565.
17. Longstreth WT Jr., Rosendaal FR, Siscovick DS et al. Risk of stroke in young women and two prothrombotic mutations; Factor V Leiden and prothrombin gene variant (G20210A). Stroke 1998; 29: 577-580.
18. Ray JG. Meta-analysis of hyperhomocysteinemia as a risk factor for venous thromboembolic disease. Archives of Internal Medicine 1998; 158: 2101-2106.
19. Hirsh J, Wakentin TE, Shaughnessy SG et al. Heparin and low-molecular-weight heparin: Mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 2001; 119: 64S-94S.
20. Flessa HC, Kapstrom AB, Glueck HI & Will JJ. Placental transport of heparin. American Journal of Obstetrics and Gynecology 1965; 9: 570-573.
21. Hall JG, Pauli RM & Wilson KM. Maternal and fetal sequelae of anticoagulation during pregnancy. American Journal of Medicine 1980; 68: 122-124.
22. Koopman M, Prandoni P, Piovella F et al. Treatment of venous thrombosis with unfractionated heparin administered in the hospital as compared with subcutaneous low molecular weight heparin administered at home. New England Journal of Medicine 1996; 334: 682-687.
23. Siragusa S, Cosmi B, Piovella F et al. Low molecular weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: Results of a meta-analysis. American Journal of Medicine 1996; 100: 269-277.
24. Anderson DR, O'Brien BJ, Levine MN et al. Efficacy and cost of low-molecular-weight heparin compared with standard heparin for the prevention of deep vein thrombosis after total hip arthroplasty. Annals of Internal Medicine 1993; 119: 1105-1112.
25. Dulitzki M, Pauzner R, Langevitz P et al. Low-molecular-weight heparin during pregnancy and delivery: Preliminary experience with 41 pregnancies. Obstetrics and Gynecology 1996; 87: 380-383.
26. Hunt BJ, Doughty H, Majumdar G et al. Thromboprophylaxis with low molecular weight heparin (Fragmin) in high risk pregnancies. Thrombosis and Haemostasis 1997; 77: 39-43.
27. Nelson-Piercy C, Letsky EA & De Swiet M. Low-molecular-weight heparin for obstetric thromboprophylaxis: Experience of sixty-nine pregnancies in sixty-one women at high risk. American Journal of Obstetrics and Gynecology 1997; 176: 1062-1068.
28. Sanson BJ, Lensing AWA, Prins MH et al. Safety of low-molecular weight heparin in pregnancy: A systemic review. Thrombosis and Haemostasis 1999; 81: 668-672.
29. Lepercq J, Conard J, Borel-Derlon A et al. Venous thromboembolism during pregnancy: A retrospective study of enoxaparin safety in 624 pregnancies. British Journal of Obstetrics and Gynaecology 2001; 108: 1134-1140.
30. Forestier F, Daffos F & Capella-Pavlovsky M. Low molecular weight heparin (PK 10159) does not cross the placenta during the second trimester of pregnancy: Study by direct fetal blood sampling under ultrasound. Thrombosis Research 1984; 34: 557-560.
31. Thomson AJ, Walker ID & Greer IA. Low-molecular-weight heparin for immediate management of thromboembolic disease in pregnancy. Lancet 1998; 352: 1904.
32. Hull RD, Raskob GE, Brant RF et al. Relation between the time to achieve the lower limit of the APTT therapeutic range and recurrent venous thromboembolism during heparin treatment for deep vein thrombosis. Archives of Internal Medicine 1997; 157: 2562-2568.
33. Casele HL, Laifer SA, Woelkers DA et al. Changes in the pharmacokinetics of the low-molecular-weight heparin enoxaparin sodium during pregnancy. American Journal of Obstetrics & Gynecology 1999; 181: 1113-1117.
34. Crowther MA, Spitzer K, Julian J et al. Pharmacokinetic profile of a low-molecular-weight heparin (Reviparin) in pregnant patients: A prospective cohort study. Thrombosis Research 2000; 98: 133-138.
35. Rodie VA, Thomson AJ, Stewart FM et al. Low molecular weight heparin for the treatment of venous thromboembolism in pregnancy: A case series. British Journal of Obstetrics and Gynaecology 2002; 109: 1020-1024.
36. Dahlman TC. Osteoporotic fractures and the recurrence of thromboembolism during pregnancy and the puerperium in 184 women undergoing thromboprophylaxis with heparin. American Journal of Obstetrics and Gynecology 1993; 158: 1265-1270.
37. Barbour LA, Kick SD, Steiner JF et al. A prospective study of heparin-induced osteopenia in pregnancy using bone densitometry. American Journal of Obstetrics and Gynecology 1994; 170: 862-869.
38. Monreal M, Lafoz E, Olive A et al. Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin. Thrombosis and Haemostasis 1994; 71: 7-11.
39. Douketis JD, Ginsberg JS, Burrows RF et al. The effects of long-term heparin therapy during pregnancy on bone density. A prospective matched cohort study. Thrombosis and Haemostasis 1996; 75: 254-257.
40. Pettila V, Leinonen P, Markkola A et al. Postpartum bone mineral density in women treated for thromboprophylaxis with unfractionated or LMW heparin. Thrombosis and Haemostasis 2002; 87: 182-186.
41. Backos M, Rai R, Thomas E et al. Bone density changes in pregnant women treated with heparin: A prospective, longitudinal study. Human Reproduction 1999; 14: 2876-2880.
42. Rai R, Cohen H, Dave M & Regan L. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). British Medical Journal 1997; 314: 253-257.
43. Kelton JG. Heparin-induced thrombocytopenia: An overview. Blood Review 2002; 15: 77-80.
44. Kelton JG, Smith JW, Warkentin TE et al. Immunoglobulin G from patients with heparin-induced thrombocytopenia binds to a complex of heparin and platelet factor 4. Blood 1994; 83: 3232-3239.
45. Chong BH, Pitney WR & Castaldi PA. Heparin-induced thrombocytopenia: Association of thrombotic complications with heparin-dependent IgG antibody that induces thromboxane synthesis and platelet aggregation. Lancet 1982; ii: 1246-1249.
46. Woo YL, Allard S, Cohen H et al. Danaparoid thromboprophylaxis in pregnant women with heparin-induced thrombocytopenia. British Journal of Obstetrics and Gynaecology 2002; 109: 466-468.
47. Huhle G, Geberth M, Hoffman U et al. Management of heparin associated thrombocytopenia with subcutaneous r-hirudin. Gynaecology and Obstetric Investigations 2000; 49: 67-69.
48. Kelton JG, Smith JW, Warkentin TE et al. Immunoglobulin G from patients with heparin-induced thrombocytopenia binds to a complex of heparin and platelet factor 4. Blood 1994; 83: 3232-3239.
49. Warkentin TE, Levine MN, Hirsh J et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. New England Journal of Medicine 1995; 332: 1330-1335.
50. Lindhoff-Last E, Nakov R, Misselwitz F et al. Incidence and clinical relevance of heparin-induced antibodies in patients with deep vein thrombosis treated with unfractionated or low-molecular-weight heparin. British Journal of Haematology 2002; 118: 1137-1142.
51. Kaplan KL & Francis CW. Direct thrombin inhibitors. Seminars in Haematology 2002; 39: 187-196.
52. Macklon NS & Greer IA. Venous thromboembolic disease in obstetrics and gynaecology: The Scottish experience. Scottish Medical Journal 1996; 41: 83-86.
53. Keam SJ & Goa KL. Fondaparinux sodium. Drugs 2002; 62: 1573-1585.
54. Turpie AG, Bauer KA, Eriksson BI & Lassen MR. Fondaparinux vs Enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: A meta-analysis of 4 randomized double-blind studies. Archives of Internal Medicine 2002; 152: 1833-1840.
55. Lagrange F, Vergnes C, Brun JL et al. Absence of placental transfer of pentasaccharide (Fondaparinux, Arixtra) in the dually perfused human cotyledon in vitro. Thrombosis and Haemostasis 2002; 87: 831-835.
56. Antiplatelet Trialists. Collaboration overview of randomised trials of antiplatelet therapy - III. Reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. Antiplatelet Trialists' Collaboration. British Medical Journal 1994; 308: 235-246.
57. No authors listed. Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary embolism prevention (PEP) trial. Lancet 2000; 355: 1295-1302.
58. No authors listed. CLASP: A randomised trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women. CLASP (Collaborative Low-dose Aspirin Study in Pregnancy) Collaborative Group. Lancet 1994; 343:619-629.
59. Hirsh J, Dalen J, Anderson DR et al. Oral anticoagulants: Mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 2001; 119(supplement. 1): 8S-21S.
60. Chan WS, Anand S & Ginsberg J. Anticoagulation of pregnant women with mechanical heart valves. A systemic review of the literature. Archives of Internal Medicine 2000; 150: 191-196.
61. Royal College of Obstetricians and Gynaecologists. Thromboembolic Disease in Pregnancy and the Puerperium: Acute Management. Guideline No 28. London: RCOG, 2001.
62. Scurr JH, Machin SJ, Bailey-King S et al. Frequency and prevention of symptomless deep-vein thrombosis in long-haul flights: A randomised trial. Lancet 2001; 357: 1485-1489.
63. Kanis JA. Heparin in the treatment of pulmonary thromboembolism. Thrombosis et Diathens Haemorrhagica 1974; 32: 519-527.
64. Ginsberg JS, Hirsh J, Rainbow AJ & Coates G. Risks to the fetus of radiologic procedures used in the diagnosis of maternal venous thromboembolic disease. Thrombosis and Haemostasis 1989; 61: 189-196.
65. Kearon C, Ginsberg JS, Douketis J et al. Management of suspected deep venous thrombosis in outpatients by using clinical assessment and D-dimer testing. Annals of Internal Medicine 2001; 135: 108-111.
66. Francalanci I, Comeglio P, Liotta AA et al. D-dimer concentrations during normal pregnancy, as measured by ELISA. Thrombosis Research 1995; 78: 399-405.
67. Horlocker TT & Heit JA. Low molecular weight heparin: Biochemistry, pharmacology, peri-operative regimens and guidelines for regional anaesthesia management. Anaesthesia and Analgesia 1997; 85: 874-875.
68. Tryba M & Wedel DJ. Central neuraxial block and low molecular weight heparin (enoxaparine): Lessons learned from different dosage regimes in two continents. Acta Anaesthesiologica Scandinavica 1997; III(supplement): 100-104.
69. Haemostasis and Thrombosis Task Force, Investigation and management of thrombophilia. In Roberts B (ed.) Standards in Haematology Practice, pp 112-127. Oxford: Blackwell Scientific Publications. 1991.
70. Richards EM, Makris M & Preston FE. The successful use of protein C concentrate during pregnancy in a patient with type 1 protein C deficiency, previous thrombosis and recurrent fetal loss. British Journal of Haematology 1997; 98: 660-661.
71. British Society for Haematology. Guidelines on oral coagulation. 3rd edn. British Journal of Haematology 1998; 101: 374-387.
72. Sallah S, Thomas DP & Roberts HR. Warfarin and heparin-induced skin necrosis and the purple toe syndrome: Infrequent complications of anticoagulant treatment. Thrombosis and Haemostasis 1997; 78: 785-790.
73. Vasilakis C, Jick H & Del Mar Melero-Montes M. Risk of idiopathic venous thromboembolism in users of progestagens alone. Lancet 1999; 354: 1610-1611.
74. Brandjes DP, Buller HR, Heijboer H et al. Randomised trial of effect of compression stockings in patients with symptomatic proximal venous thrombosis. Lancet 1997; 349: 759-762.
75. Millar DS, Allgrove J, Rodeck C et al. A homozygous deletion/insertion mutation in the protein C (PROC) gene causing neonatal purpura fulminans: Prenatal diagnosis in an at risk pregnancy. Blood Coagulation and Fibrinolysis 1994; 5: 647-649.
76. Lane DA, Auberger J, Ireland H et al. Prenatal diagnosis in combined antithrombin and FV mutation. British Journal of Haematology 1996; 94: 753-755.
77. Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematologica 1957; 17: 237-246.
78. Eckman MH, Levine HJ & Pauker SG. Effect of laboratory variation in the prothrombin-time ratio on the results of oral anticoagulant therapy. New England Journal of Medicine 1993; 329: 696-702.
79. Makris M, Greaves M, Phillips WS et al. Emergency oral anticoagulant reversal: The relative efficacy of infusions of fresh frozen plasma and clotting factor concentrate on correction of the coagulopathy. Thrombosis and Haemostasis 1997; 77: 477-480.
80. Stainsby D, MacLennan S & Hamilton PJ. Management of massive blood loss: A template guideline. British Journal of Anaesthesia 2000; 85: 487-491.